FILTER

Refine your search with the following facets to narrow down your results.

8 Current news of Elbion

Biotie Therapies completes acquisition of pharmaceutical development company elbion

18-Nov-2008 - Biotie Therapies Corp. has entered into an agreement with elbion NV on the acquisition of its fully owned subsidiary, elbion GmbH. To complete the transaction, the Board of Directors of Biotie has proposed to the General Meeting of Shareholders of Biotie to be convened on 14 November 2008 that ...

Biotie to acquire neurology and immunology focussed pharmaceutical company elbion GmbH

29-Oct-2008 - Biotie Therapies has entered into an agreement to acquire the German pharmaceutical company elbion GmbH. The combination of the two businesses will take place by a share exchange and create a leading European company in the field of discovery and development of therapeutics for central nervous ...

addiction central nervous system Finland +6

elbion and Wyeth Enter Collaboration to Develop New Treatments for Schizophrenia

06-Feb-2007 - elbion NV announced it has entered a research and license agreement with Wyeth Pharmaceuticals, a division of Wyeth, around elbion's phosphodiesterase 10 (PDE10) program for CNS disorders with an initial focus on schizophrenia. The agreement includes an upfront payment, milestones and research ...

CNS disorders Germany license agreements +4

elbion Merges With 4AZA to Form European Drug Discovery and Development Company

08-Dec-2006 - elbion AG announced it has merged with 4AZA Bioscience NV, Belgium, to form a European company for discovery and development of drugs for CNS and immunological diseases. The combined company, to be called elbion NV ("elbion"), will be headquartered at 4AZA's current site in Leuven, where it will ...

Belgium business development diseases +2

elbion AG appoints Dr. Thomas Taapken as Chief Financial Officer and Member of the Executive Board

23-Sep-2005 - elbion AG announced that Dr. Thomas Taapken has been appointed Chief Financial Officer by the supervisory board of the company. Taapken (40), previously spent 3 years as a Partner in the life science team of DVC, Deutsche Venture Capital, and was a member of the supervisory board of elbion AG. ...

Life Science Sanofi-aventis

elbion AG Increases Series A Financing to EUR35 Million

30-May-2005 - elbion AG (elbion) announced that it has increased its Series A Financing from EUR25 million to EUR35 million. Additional investors include Techno Venture Management (TVM), Munich and Boston, Temasek Holdings, Singapore, and Mitsubishi Corporation, Tokyo. They complement lead investors 3i, ...

bases Mitsubishi Singapore

Glaxosmithkline and Elbion to Collaborate on Development and Commercialisation of a new DE IV Inhibitor

25-Jan-2005 - GlaxoSmithKline plc (GSK) and elbion AG announce that they have signed a worldwide agreement to collaborate on the development and commercialisation of elbion's phosphodiesterase (PDE) IV inhibitor, AWD 12-281 and associated back-up compounds. AWD 12-281 is currently in phase II clinical studies ...

allergic rhinitis asthma clinical trials +5

elbion AG Completes EUR 25 Million Series A Financing

11-Jan-2005 - Elbion AG (elbion), announced that it has secured a EUR 25 million first round of venture capital financing. The private placement was co-led by 3i (Munich, Germany), Burrill & Company (San Francisco, USA) and DVC Deutsche Venture Capital (Munich, Germany). Also participating in the round were ...

diseases Germany USA